TY - JOUR T1 - Sulbactam/Durlobactam: First Approval. A1 - Keam,Susan J, PY - 2023/8/29/medline PY - 2023/7/31/pubmed PY - 2023/7/31/entrez SP - 1245 EP - 1252 JF - Drugs JO - Drugs VL - 83 IS - 13 N2 - Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Coadministration of durlobactam (a β-lactamase inhibitor with potent activity against a broad range of serine β-lactamases) with sulbactam (an established class A β-lactamase inhibitor with antibacterial activity against A. baumannii) prevents sulbactam degradation by ABC-produced β-lactamases. In May 2023, sulbactam/durlobactam was approved in the USA for use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of ABC. This article summarizes the milestones in the development of sulbactam/durlobactam leading to this first approval for the treatment of infections caused by ABC. SN - 1179-1950 UR - https://www.unboundmedicine.com/medline/citation/37523122/Sulbactam_Durlobactam:_First_Approval DB - PRIME DP - Unbound Medicine ER -